[go: up one dir, main page]

MX2012014387A - Dispersiones solidas que contienen inhibidores de cinasa. - Google Patents

Dispersiones solidas que contienen inhibidores de cinasa.

Info

Publication number
MX2012014387A
MX2012014387A MX2012014387A MX2012014387A MX2012014387A MX 2012014387 A MX2012014387 A MX 2012014387A MX 2012014387 A MX2012014387 A MX 2012014387A MX 2012014387 A MX2012014387 A MX 2012014387A MX 2012014387 A MX2012014387 A MX 2012014387A
Authority
MX
Mexico
Prior art keywords
solid dispersion
cinasa
compound
solid dispersions
dispersions containing
Prior art date
Application number
MX2012014387A
Other languages
English (en)
Inventor
Jonathan Miller
Yi Gao
Eric A Schmitt
Rajeev Gokhale
Justin Lafountaine
Lloyd Dias
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44475097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012014387(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2012014387A publication Critical patent/MX2012014387A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describe una dispersión sólida que comprende, en forma esencialmente no cristalina, un compuesto inhibidor de cinasa, por ejemplo N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tie no[3, 2-c] piridin-3-iI}fenil)N'-(3-fluorofeniI)urea, disperso en una matriz sólida que comprende (a) un transportador polimérico soluble en agua farmacéuticamente aceptable y (b) un tensoactivo farmacéuticamente aceptable. Un proceso para preparar una dispersión sólida, en donde el proceso comprende disolver el compuesto, el transportador polimérico y el tensoactivo y tener el compuesto disperso en el mismo, en forma esencialmente no cristalina. La dispersión sólida es adecuada para administración oral a un sujeto que necesita de tratamiento para un cáncer.
MX2012014387A 2010-06-09 2011-06-07 Dispersiones solidas que contienen inhibidores de cinasa. MX2012014387A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35286210P 2010-06-09 2010-06-09
PCT/US2011/039430 WO2011156361A2 (en) 2010-06-09 2011-06-07 Solid dispersions containing kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2012014387A true MX2012014387A (es) 2013-05-01

Family

ID=44475097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014387A MX2012014387A (es) 2010-06-09 2011-06-07 Dispersiones solidas que contienen inhibidores de cinasa.

Country Status (27)

Country Link
US (1) US8557995B2 (es)
EP (1) EP2579855B1 (es)
JP (1) JP5758486B2 (es)
KR (1) KR20130109092A (es)
CN (1) CN103002880B (es)
AR (1) AR081845A1 (es)
AU (1) AU2011264993B2 (es)
BR (1) BR112012031516A2 (es)
CA (1) CA2802021A1 (es)
CL (1) CL2012003446A1 (es)
CO (1) CO6640325A2 (es)
CR (1) CR20120647A (es)
DO (1) DOP2012000306A (es)
EC (1) ECSP13012364A (es)
ES (1) ES2523999T3 (es)
GT (1) GT201200333A (es)
MX (1) MX2012014387A (es)
NZ (1) NZ605434A (es)
PE (1) PE20130231A1 (es)
PH (1) PH12012502432A1 (es)
RU (1) RU2566716C2 (es)
SG (2) SG2014013502A (es)
TW (1) TW201202234A (es)
UA (1) UA108886C2 (es)
UY (1) UY33437A (es)
WO (1) WO2011156361A2 (es)
ZA (1) ZA201300108B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987406A (zh) * 2011-12-14 2014-08-13 艾伯维公司 含有激酶抑制剂的组合物
WO2014024210A2 (en) * 2012-08-10 2014-02-13 Hetero Research Foundation Novel polymorphs of doxercalciferol
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
US9249134B2 (en) * 2013-03-26 2016-02-02 Cadila Healthcare Limited Process for preparation of amorphous form of dasatinib
CN111635353A (zh) * 2013-07-19 2020-09-08 西佳技术公司 非晶形特考韦瑞制备
EP3089736B1 (en) * 2013-12-31 2025-07-23 Ascendia Pharmaceuticals, LLC Pharmaceutical compositions for poorly water-soluble compounds
EP3120871B1 (en) * 2014-03-18 2023-06-28 Takeda Pharmaceutical Company Limited Solid dispersion
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
WO2015200635A1 (en) * 2014-06-25 2015-12-30 Abbvie Inc. N-(4-{4-AMINO-7-[1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-yl]THIENO[3,2-c]PYRIDIN-3-YL}PHENYL)-N'-(3-FLUOROPHENYL)UREA DOCUSATE
HUE047477T2 (hu) * 2015-06-04 2020-04-28 Pfizer Palbociclib szilárd dózisformái
US10449195B2 (en) * 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN105816437B (zh) * 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
MX2021010692A (es) * 2019-03-04 2021-10-01 Japan Tobacco Inc Dispersion solida amorfa de compuesto de pirazol-amida.
CN110946829A (zh) * 2019-12-30 2020-04-03 上海景峰制药有限公司 一种阿瑞匹坦固体分散体及其制备方法和应用
CA3168667A1 (en) 2020-01-24 2021-07-29 Nanocopoeia, Llc Amorphous solid dispersions of dasatinib and uses thereof
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
EP4255495A4 (en) 2020-12-03 2025-10-08 Battelle Memorial Institute COMPOSITIONS OF POLYMERIC NANOPARTICLES AND DNA NANOSTRUCTURES AND METHODS FOR NON-VIRAL DELIVERY
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2023283616A1 (en) * 2021-07-09 2023-01-12 Regents Of The University Of Minnesota Amorphous solid dispersion of sorafenib and solid formualtion comprising the same
NL2028762B1 (en) * 2021-07-16 2023-01-23 Seranovo Holding B V Micelle-generating formulations for enhanced bioavailability
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
CN116942897B (zh) * 2023-07-26 2025-10-31 同光(昆山)生物科技有限公司 一种改性骨水泥及其制备方法和应用
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
WO2003047579A1 (en) * 2001-12-03 2003-06-12 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
CA2474958A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
EP1469829B1 (en) 2002-02-01 2016-01-27 Bend Research, Inc Immediate release dosage forms containing solid drug dispersions
WO2003063822A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
DE602005007048D1 (de) 2004-08-27 2008-07-03 Bayer Pharmaceuticals Corp Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2008012617A1 (en) 2006-07-21 2008-01-31 Pfizer Products Inc. Drying of drug-containing particles
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
JP2011500649A (ja) * 2007-10-19 2011-01-06 アボット ゲーエムベーハー ウント カンパニー カーゲー Ｎ−アリール尿素系薬剤の固体分散体生成物
RS55157B2 (sr) 2008-10-07 2023-10-31 Kudos Pharm Ltd Farmaceutska formulacija 514
UY32291A (es) * 2008-12-05 2010-07-30 Abbott Lab Inhibidores de quinasa con perfiles de seguridad cyp mejorados
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型

Also Published As

Publication number Publication date
CA2802021A1 (en) 2011-12-15
GT201200333A (es) 2014-06-10
SG2014013502A (en) 2014-05-29
RU2566716C2 (ru) 2015-10-27
WO2011156361A3 (en) 2012-07-05
AU2011264993B2 (en) 2014-02-06
ES2523999T3 (es) 2014-12-03
ECSP13012364A (es) 2013-01-31
EP2579855A2 (en) 2013-04-17
SG186248A1 (en) 2013-01-30
PH12012502432A1 (en) 2013-02-11
CN103002880A (zh) 2013-03-27
TW201202234A (en) 2012-01-16
JP5758486B2 (ja) 2015-08-05
KR20130109092A (ko) 2013-10-07
AU2011264993A1 (en) 2013-01-24
UA108886C2 (ru) 2015-06-25
CL2012003446A1 (es) 2013-04-05
US8557995B2 (en) 2013-10-15
DOP2012000306A (es) 2013-01-31
ZA201300108B (en) 2013-09-25
PE20130231A1 (es) 2013-04-04
WO2011156361A2 (en) 2011-12-15
CN103002880B (zh) 2015-01-28
US20110306632A1 (en) 2011-12-15
AR081845A1 (es) 2012-10-24
UY33437A (es) 2012-01-31
RU2012156254A (ru) 2014-07-20
BR112012031516A2 (pt) 2016-11-08
CR20120647A (es) 2013-04-08
EP2579855B1 (en) 2014-09-03
NZ605434A (en) 2014-03-28
JP2013528218A (ja) 2013-07-08
HK1182327A1 (en) 2013-11-29
CO6640325A2 (es) 2013-03-22

Similar Documents

Publication Publication Date Title
MX2012014387A (es) Dispersiones solidas que contienen inhibidores de cinasa.
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
NZ603364A (en) Inhibitors of arginase and their therapeutic applications
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
TW200716628A (en) Novel compounds
MX2010001574A (es) Ligandos del receptor cannabinoide.
CL2011000625A1 (es) Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida.
MX341342B (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
ES2582660T3 (es) Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina
MX2010004235A (es) Piperidinas tri-sustituidas.
EA201000889A1 (ru) Тризамещенные пиперидины в качестве ингибиторов ренина
BR112014014342A2 (pt) composições contendo inibidores de cinase
CL2008003091A1 (es) Forma cristalina 1 de etanolato de n-(4-(3-amino-1h-indazol-4il)fenil)-n-(2-fluoro-5-metilfenil)urea. 1/4; composicion farmaceutica; y uso en el tratamiento de cancer en un mamifero.
WO2007145563A8 (en) Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor
EA201000720A1 (ru) 4,4-дизамещённые пиперидины как ингибиторы ренина
EA201000882A1 (ru) Соединение, его применение и фармацевтическая композиция, содержащая это соединение
CL2009002018A1 (es) Uso de un inhibidor de esfingosina-1-fosfato (s1p) liasa para tratar la malaria cerebral incluyendo compuestos derivados de imidazol-alquilamina; uso de un inhibidor de s1p liasa y un agente activo adicional; formulacion farmaceutica y forma farmaceutica que comprende un inhibidor de s1p liasa y un farmaco antimalaria.
WO2011156464A8 (en) Crystalline forms of kinase inhibitors
CL2008003090A1 (es) Forma cristalina 1 del etanoato de n-{4-(3-amino-1h-indazol-4-il)fenil}-n'-(2-fluoro-5-metilfenil)urea*1/4; procedimiento de preparacion; composicion farmaceutica que la comprende; utiles en el tratamiento del cancer.
MX2012014385A (es) Formas cristalinas de inhibidores de cinasa.
HK1182383A1 (zh) 激酶抑制剂的结晶形式
WO2012075287A3 (en) Novel selective inhibitors of prolylcarboxypeptidase
TH139647A (th) สารกระจายชนิดแข็งที่ประกอบด้วยสารยับยั้งไคเนส (solid dispersions containing kinase inhibitors)

Legal Events

Date Code Title Description
FG Grant or registration